Target Audience
- Researchers and technical professionals familiar with the fundamentals of next-generation sequencing (NGS) and genomic analysis who want to understand the companies shaping the industry.
- Readers interested in the competitive dynamics of the NGS market, particularly Illumina's position and the technological and business strategies of Chinese companies.
- Scientists and industry professionals seeking to understand how short-read sequencing, long-read sequencing, and spatial omics may evolve and influence the future of genomic research.
Executive Summary
- MGI Tech has established a competitive short-read NGS platform based on its proprietary DNBSEQ technology, positioning itself as a credible alternative to Illumina.
- In 2026, MGI acquired CycloneSEQ and STOmics, reinforcing its strategy to integrate long-read sequencing, spatial omics, and AI-enabled laboratory automation.
- Although revenue and operating cash flow have shown signs of recovery, the company remains unprofitable. Growth in recurring consumables revenue and international expansion will be critical to its financial future.
- China's drive toward domestic technological self-sufficiency provides favorable market conditions, while geopolitical risks, including the U.S. BIOSECURE Act, create uncertainty for international expansion.
- The period from 2027 to 2030 may determine whether MGI remains primarily a China-centered NGS manufacturer or evolves into a major global multi-omics platform company.
1. What Kind of Company Is MGI Tech?
MGI Tech (华大智造, Shanghai Stock Exchange: 688114) is one of the most important companies in today's global genomics industry.
Its significance extends well beyond offering sequencing instruments at lower prices than Illumina.
Building on its proprietary DNBSEQ technology, MGI has been expanding from short-read NGS into long-read sequencing, spatial omics, and laboratory automation.
The year 2026 marked a particularly important turning point.
In March 2026, MGI acquired and integrated CycloneSEQ, a nanopore sequencing technology company, and STOmics, a spatial omics company, from within its broader corporate group.
This transaction made clear its ambition to transform from an NGS instrument manufacturer into a provider of comprehensive omics analysis platforms.[1]
Five points are particularly important for understanding MGI's current position and future strategy.
-
Its short-read sequencing technology is already competitive. DNBSEQ offers a practical alternative to Illumina's sequencing-by-synthesis (SBS) technology. It should not be regarded simply as a lower-cost substitute.
-
Its financial performance is recovering, but profitability remains a challenge. Revenue increased by approximately 12% year over year during the first nine months of 2026, and operating cash flow turned positive. However, the company continued to report a net loss.
-
Its business strategy is undergoing a major transition. MGI is shifting its emphasis from expanding the installed base of sequencing instruments toward recurring revenue from reagents and consumables, while developing integrated solutions combining multiple omics technologies.
-
Geopolitical risk remains one of its greatest uncertainties. China's demand for domestically developed technologies provides a tailwind, but procurement restrictions, data governance concerns, and supply-chain issues could constrain growth in Western markets.
-
The key question for the next three to five years is whether MGI can establish a sustainable ecosystem and recurring revenue model. Technological competitiveness alone will not be sufficient.
In short, MGI has already become a credible technological alternative to Illumina, but its global business infrastructure and market position are still developing.
2. MGI's Current Financial Position
When evaluating MGI, it is essential to distinguish the pace of technological innovation from actual financial performance.
2.1 Recent Financial Results
MGI's third-quarter financial report, published on October 24, 2026, presented the following results.[2]
| Metric | January–September 2026 | Year-over-year comparison |
|---|---|---|
| Revenue | RMB 2.150 billion | +11.98% |
| Net profit attributable to shareholders of the parent company | −RMB 187 million | Loss continued, but improved |
| Operating cash flow | +RMB 450 million | Turned positive from the previous year's negative figure |
The year-over-year figures reflect retrospective adjustments associated with the acquisitions of STOmics and CycloneSEQ.
MGI's revenue trend is shown below.[2][3]
| Period | Revenue |
|---|---|
| 2023 | RMB 2.911 billion |
| 2024 | RMB 3.013 billion |
| 2025 | RMB 2.780 billion |
| January–September 2026 | RMB 2.150 billion |
The 2026 figure represents only the first nine months and therefore cannot be directly compared with full-year revenue figures.
Revenue declined by 7.73% in 2025, but the company showed signs of recovery in 2026.
Its net loss for 2025 was approximately RMB 222 million, an improvement from approximately RMB 601 million in 2024.[3]
Nevertheless, revenue growth in the third quarter of 2026 alone was only 1.65% year over year. This indicates that growth was not accelerating continuously.
At the same time, gross profit margin for the first nine months of 2026 improved by 3.84 percentage points compared with the previous year.[2]
2.2 How Should We Interpret These Financial Results?
These developments suggest several important trends.
- MGI appears to be moving from an investment phase focused on expanding instrument installations toward a phase that places greater emphasis on increasing reagent consumption by existing customers.
- Cost reductions and working capital management have contributed to improving cash flow.
- However, a stable and consistently profitable growth model has not yet been demonstrated.
This distinction is particularly important in the life science instrumentation industry.
Selling a sequencer is only the beginning of a long-term customer relationship.
Over time, financial performance depends heavily on how frequently installed instruments are used and how much reagent and other consumable revenue they generate.
3. MGI's Core Technology: Why Does DNBSEQ Matter?
MGI's core technology is DNA Nanoball Sequencing (DNBSEQ).
3.1 Similarities and Differences Compared with Illumina
Like Illumina's widely used short-read sequencing-by-synthesis technology, DNBSEQ identifies nucleotide sequences through fluorescence-based detection.
However, the two technologies differ substantially in how DNA templates are prepared and presented on the flow cell.
Illumina platforms generally generate DNA clusters through bridge amplification or related approaches on the flow cell.
MGI, by contrast, produces DNA nanoballs (DNBs) in advance using rolling circle amplification (RCA), then deposits them onto the flow cell.
The basic DNBSEQ workflow is as follows.
- DNA fragments are converted into sequencing libraries.
- Library molecules are circularized.
- Rolling circle amplification generates DNA nanoballs containing many copies derived from the same template molecule.
- DNBs are deposited onto a patterned flow cell.
- Sequencing is performed using chemistry centered on combinatorial Probe-Anchor Synthesis (cPAS).
The key distinction is that DNA amplification does not need to occur directly on the flow cell. Instead, preformed DNBs are arranged and sequenced.
In principle and in practice, this architecture offers several potential advantages.
- Cluster density and spatial uniformity can be controlled more effectively.
- The design can reduce variability associated with clonal amplification directly on the flow cell.
- Because copy generation during DNB formation primarily involves linear amplification, it may reduce the accumulation of errors associated with exponential PCR amplification.
- High-density arraying and rapid imaging can enable high-throughput sequencing.
However, DNBSEQ library preparation may still involve PCR.
Furthermore, actual sequencing error rates, GC bias, duplicate rates, and index misassignment depend on library preparation, sequencing chemistry, instruments, and computational pipelines.
Therefore, it would be incorrect to conclude that DNBSEQ is inherently more accurate than Illumina simply because it uses DNA nanoballs.
3.2 Evidence Regarding Sequencing Data Quality
A study published in FEBS Letters in 2025 compared Illumina and MGI platforms using single-cell RNA sequencing data from three human cancer samples.
The researchers reported that platform differences did not substantially alter the main conclusions regarding cellular clustering and gene expression analysis.[4]
In addition, MGI highlighted a whole-genome sequencing benchmark using HG002/NA24385 in 2026.
The comparison included DNBSEQ-T7+, T1+, and T7 alongside NovaSeq 6000, Element AVITI, and PacBio Onso.
MGI reported favorable Q30 metrics and variant-calling performance for its platforms.[5]
However, such comparisons require careful interpretation.
Q30 values depend on platform-specific quality estimation and calibration methods. Consequently, identical Q30 values across different platforms do not necessarily represent identical empirically measured error rates.
From a genomics research perspective, more meaningful evaluation criteria include the following.
| Evaluation Area | Scientifically Important Metrics |
|---|---|
| SNVs and small indels | Precision, recall, and F1 score against Genome in a Bottle (GIAB) truth sets |
| Difficult genomic regions | Callability in high-GC, repetitive, pseudogene-rich, and low-complexity regions |
| Somatic variants | Error profiles at low variant allele fractions (VAFs), including background noise after UMI-based correction |
| RNA-seq | GC bias, transcript quantification, and detection of low-abundance genes |
| Single-cell RNA-seq | Cell barcode and UMI integrity, cell identification, and ambient RNA effects |
| Operational performance | Total cost per usable gigabase, rerun rates, and turnaround time |
For conventional whole-genome sequencing, RNA-seq, whole-exome sequencing, and population genomics, MGI represents a highly competitive platform.
However, compatibility with Illumina should not be assumed without validation, particularly for specialized assays and difficult genomic regions.
4. Product Portfolio and Competitive Positioning
MGI offers a broad range of sequencing instruments, from relatively low-throughput systems to ultra-high-throughput platforms.
4.1 Major Sequencing Platforms
DNBSEQ-G99 / G50 / G400
These instruments serve laboratory-scale NGS applications, including whole-exome sequencing, RNA-seq, oncology panels, and relatively moderate-scale whole-genome sequencing.
They compete in markets where Illumina NextSeq and Element AVITI are also considered.
DNBSEQ-T7 / T7+ / T1+
These systems target high-throughput whole-genome sequencing, population genomics, cancer genomics, and transcriptomic applications.
A major selling point of the T7 family is its capacity for processing large numbers of samples at competitive per-run economics.
DNBSEQ-T20×2
The T20×2 is designed for ultra-high-throughput sequencing.
According to official product documentation, it offers a maximum specified output of approximately 72 Tb.[6]
Potential applications include national or regional genome projects and large-scale sequencing centers.
It is important to note that maximum output depends on operating conditions and does not necessarily correspond to the number of usable reads generated in a particular assay.
4.2 Competitive Landscape
MGI competes with companies beyond Illumina.
| Company / Technology | Key Strengths | Competitive Relationship with MGI |
|---|---|---|
| Illumina | Extensive installed base, mature library preparation and software ecosystem, strong clinical infrastructure | Principal competitor in short-read sequencing |
| Element Biosciences | AVITI platform quality, flexibility, and differentiated applications | Competition among medium-scale research laboratories |
| Ultima Genomics | High-throughput sequencing designed to achieve very low costs | Price competition in large-scale WGS and high-volume applications |
| PacBio | HiFi long reads, high-accuracy structural variant analysis, de novo assembly | Both competitive and complementary to CycloneSEQ |
| Oxford Nanopore Technologies | Ultra-long DNA reads, real-time analysis, direct RNA sequencing, methylation detection | Direct technological competitor to CycloneSEQ |
One particularly important point is that competing with Illumina alone is no longer sufficient.
Although the cost of short-read sequencing continues to decline, customers increasingly evaluate platforms based on factors beyond cost per nucleotide.
These include sample preparation, analytical quality, turnaround time, and the clinical utility of generated data.
For MGI to achieve substantial future growth, it will need to offer application-specific, optimized workflows rather than relying exclusively on instrument-level advantages.
5. The Major Strategic Shift in 2026: SEQALL + GLI + Omics
The acquisitions of STOmics and CycloneSEQ in March 2026 represent one of the most important developments in understanding MGI's long-term strategy.
They represent much more than an expansion of the product catalog.
MGI is seeking to transition from dependence on short-read sequencing instrument revenue toward providing complete workflows across multiple omics applications.[1]
The strategy centers on three main areas.
| Strategic Area | Technology / Business Direction | Target Applications and Workflows |
|---|---|---|
| SEQALL | Short-read + Long-read | WGS, RNA analysis, structural variants, epigenomics |
| Omics | Spatial / Cell Omics | Spatial transcriptomics and cellular analysis |
| GLI | Generative Lab Intelligence | Automation, AI, and laboratory workflows |
By combining these capabilities, MGI aims to establish an end-to-end platform extending from sample processing and data acquisition to multi-omics integration and research or clinical applications.
However, this describes the company's strategic direction. It does not mean that complete technical integration has already been achieved.
5.1 CycloneSEQ: Entering the Long-Read Sequencing Market
CycloneSEQ is a long-read sequencing technology based on nanopore sensing.
Its fundamental principle resembles that used by Oxford Nanopore Technologies (ONT): nucleotide sequences are inferred from changes in electrical current as nucleic acid molecules pass through a nanopore.
According to MGI, CycloneSEQ was introduced in 2024 and integrates BioMEMS, ASICs, high-density nanopore sensors, and deep learning-based basecalling.
Official technical materials claim basecalling accuracy above 99% using proprietary models.[7]
However, this is a company-reported performance figure.
It does not establish that CycloneSEQ achieves accuracy equivalent to PacBio HiFi under all sequencing conditions.
For CycloneSEQ to compete effectively in the long-read market, several performance characteristics will be critical.
- Raw-read accuracy and consensus accuracy
- Read length distributions, especially N50 and the proportion of ultra-long reads
- Error characteristics in homopolymers and repetitive sequences
- Performance in structural variant detection, repeat expansions, and complex HLA regions
- Native DNA modification detection, including CpG methylation
- Software maturity, usability, and reproducibility
At present, independent validation remains insufficient to conclude that MGI's long-read technology performs at the same level as ONT or PacBio.
Nevertheless, establishing a domestic long-read sequencing technology that does not depend on ONT or PacBio could have significant strategic value in China.
Furthermore, MGI already has an installed base of short-read sequencing customers.
This creates opportunities to cross-sell long-read systems to existing customers who want to expand their analytical capabilities.
5.2 STOmics: Spatial Omics as a New Growth Opportunity
The central technology of STOmics is Stereo-seq (SpaTial Enhanced REsolution Omics-sequencing).
Stereo-seq uses chips containing densely arranged DNA nanoballs with spatial barcodes to capture transcripts from tissue sections.
A particularly important feature is that DNA nanoball technology underlies both MGI's short-read sequencing platforms and its spatial transcriptomics technology.
This creates potentially valuable technological synergies.
For example, Stereo-seq is designed to combine high-density spatial barcoding with the ability to analyze relatively large tissue areas.
However, the physical pitch of spatial barcodes should not be confused with the effective spatial resolution of gene detection.[8]
The spatial omics market includes several established and emerging competitors, including 10x Genomics, Bruker's technologies acquired from NanoString, and Vizgen.
Even if Stereo-seq offers competitive performance in high-density and large-area spatial profiling, adoption will depend on multiple factors.
- Gene detection sensitivity and UMI recovery efficiency
- Compatibility with FFPE samples and robustness to tissue quality
- Data quality across different tissue types
- Registration of imaging data with spatial gene expression information
- Cell segmentation and downstream analytical tools
- Total cost per sample, including chips, reagents, and sequencing
As research progresses from single-cell analysis toward spatial multi-omics, MGI may be able to establish a differentiated position in this field.
5.3 GLI: AI and Laboratory Automation
GLI stands for Generative Lab Intelligence, MGI's broader vision for intelligent laboratory operations.
Rather than selling sequencing instruments and automated liquid-handling robots as separate products, the company aims to integrate experimental design, sample preparation, instrument operation, quality control, and data analysis.
One important future capability will be the ability of AI systems not merely to interpret analytical results, but also to adjust subsequent experimental conditions in response to quality control findings.
This could create substantial business opportunities.
However, it is essential to distinguish MGI's existing GLI-related products and deployment experience from its longer-term vision.
6. The Core Business Strategy: From Instrument Sales to Recurring Consumables Revenue
In its 2025 annual report, MGI explicitly described a strategy of prioritizing instrument market share and expanding its installed base to generate future consumables revenue.[3]
This business model is similar to Illumina's.
The central challenge is that selling more instruments does not necessarily improve profitability if those instruments are not used frequently enough.
6.1 Business Segment Structure in 2025
MGI reported RMB 2.733 billion in revenue from its principal business segments in 2025, distributed as follows.[9]
| Business Segment | Revenue | Approximate Share |
|---|---|---|
| Sequencing | RMB 2.203 billion | 81% |
| Multi-omics | RMB 276 million | 10% |
| Smart automation | RMB 254 million | 9% |
| Total | RMB 2.733 billion | 100% |
Sequencing accounted for approximately 81% of principal business revenue, while multi-omics represented only about 10%.
However, the multi-omics segment grew by 47.83% year over year.[9]
These figures reflect the reporting structure before the acquisition of the long-read sequencing business.
During the first half of 2026, sequencing consumables revenue increased by 16% year over year, while instrument revenue declined by 6%.[10]
This indicates growth in revenue sources beyond instrument sales.
However, growth in consumables revenue alone does not prove that utilization per installed instrument has improved.
6.2 Key Metrics for Evaluating the Business Model
Several indicators deserve particular attention when assessing MGI's long-term financial prospects.
| Metric | Why It Matters |
|---|---|
| Sequencing reagent revenue growth | Measures expansion of recurring revenue |
| Active installed base | Indicates the number of instruments actually in operation |
| Consumables consumption per instrument | Measures utilization efficiency, often more informative than total installations |
| Consumables gross margin | Reveals the economics of the recurring revenue model |
| Customer retention and contract renewal rates | Indicates ecosystem competitiveness and customer loyalty |
| Instrument utilization outside China | Measures the sustainability of international market penetration |
Public disclosures do not currently provide all these indicators under consistent definitions.
Consequently, the economics of MGI's consumables business are among the most important factors for forecasting future profitability, yet they remain difficult for external observers to assess.
7. International Expansion and Geopolitical Risks
MGI is a China-based global life science company, but its operating environment differs substantially across regions.
7.1 Geographic Revenue Distribution
MGI's 2025 revenue distribution was as follows.[9]
| Region | Revenue |
|---|---|
| China | RMB 1.872 billion |
| Europe and Africa | RMB 402 million |
| Americas | RMB 243 million |
| Asia-Pacific | RMB 216 million |
Markets outside China accounted for approximately 31.5% of revenue.
The geographic classifications follow MGI's corporate disclosures.
7.2 China: Domestic Technology Development and Genomic Medicine
China offers several favorable conditions for MGI.
First, the country's policy environment emphasizes domestic development of advanced scientific instruments and greater supply-chain independence.
Second, several application areas could generate substantial sequencing demand, including genomic medicine, oncology, prenatal testing, infectious disease surveillance, and agricultural genomics.
However, growth may also be constrained by domestic instrument price competition, procurement budgets at medical institutions, clinical reimbursement systems, and regulatory approval requirements.
China's strong domestic demand represents an important competitive advantage for MGI, but it does not automatically guarantee high profitability.
7.3 Europe, Asia, and Other Regions: Localization Is Essential
Outside China, competitive pricing alone is insufficient.
Local regulatory compliance, quality assurance, after-sales service, and data processing infrastructure are also important.
For large university and research institution projects, establishing a second sequencing platform independent of Illumina can provide meaningful strategic value.
In its 2025 annual report, MGI outlined an international strategy combining technology licensing, solution delivery, and local ecosystem development.[3]
This can be interpreted as a transition from simple instrument exports toward building local capabilities for instruments, reagents, and services.
7.4 The United States: Responding to the BIOSECURE Act
U.S. policy is an unavoidable consideration when evaluating MGI's future.
Regarding its patent disputes with Illumina, a settlement in 2022 resolved major U.S. litigation and opened a path for MGI products to be commercialized in the United States.
The agreement also included provisions concerning a three-year litigation standstill.[11]
However, resolving patent litigation is not the same as securing stable access to the U.S. market.
The U.S. National Defense Authorization Act enacted on December 18, 2025, included a revised version of the BIOSECURE Act.
The legislation established mechanisms for restricting the use of biotechnology companies in contexts involving federal procurement, contracts, and grants.
Importantly, unlike the earlier 2024 proposal, the enacted legislation did not explicitly name MGI, BGI, or Complete Genomics in its statutory text.
The designation of covered companies and specific implementation requirements must therefore be evaluated separately.[12]
Consequently, it would be inaccurate to describe MGI products as being subject to a comprehensive sales ban in the United States.
Nevertheless, several risks remain.
Future company designations, procurement decisions by federally funded institutions, and institution-specific risk management policies could restrict commercial opportunities.
Genomic data security also requires a distinction between political concerns and demonstrable technical risks in specific systems.
Relevant assessment criteria include:
- Instrument communication protocols
- Dependence on cloud services
- Controls over data transfer
- Availability of on-premises data analysis
- Audit logs and traceability
- Remote maintenance access permissions
The fact that a company is headquartered in China does not, by itself, establish that a particular instrument transfers data improperly.
8. Strategic Outlook for 2027–2030: Three Scenarios
The central question for MGI's future is whether it can move beyond competition based primarily on sequencing cost and develop a higher-value business centered on analytical applications and recurring consumables revenue.
The following scenarios are analytical possibilities based on technology, competition, and financial performance.
They are not official company forecasts.
8.1 Growth Scenario: Becoming a Global Multi-Omics Platform Company
Under this scenario, MGI continues expanding its short-read installed base while generating growing recurring revenue from consumables.
CycloneSEQ and Stereo-seq become established in research markets, and the company successfully expands internationally through local partnerships.
In this case, MGI could move beyond its current position as an alternative to Illumina and become a major provider of comprehensive omics platforms.
8.2 Base Scenario: Remaining a Strong China-Centered NGS Platform Company
Under this scenario, MGI continues growing its installed base and consumables revenue in China.
However, geopolitical constraints and strong existing competitors limit the pace of market penetration in Europe and North America.
CycloneSEQ and Stereo-seq gain adoption in selected applications, while short-read sequencing and associated consumables remain the main sources of revenue for the foreseeable future.
8.3 Low-Growth Scenario: Price Competition and Geopolitical Fragmentation
Under this scenario, domestic price competition intensifies while procurement restrictions and cautious customer behavior constrain overseas sales.
Instrument sales volumes may remain stable, but reagent utilization and profit margins fail to improve sufficiently.
At the same time, returns on R&D investments in new business areas could take longer than expected.
8.4 What Will Determine the Outcome?
At present, the available evidence is insufficient to determine which scenario will ultimately unfold.
Nevertheless, the improvement in operating cash flow during 2026 is a positive development for the company's near-term operating position.
9. What Should Genomics Experts Monitor Going Forward?
Five areas are particularly important for evaluating MGI's future development.
| Area | Key Milestones to Monitor | Strategic Significance |
|---|---|---|
| DNBSEQ | Independent benchmarks using GIAB, clinical specimens, and single-cell assays | Practical feasibility of transitioning from Illumina |
| CycloneSEQ | External validation of read accuracy, N50, structural variant calling, and methylation calling | Competitiveness against ONT and PacBio |
| Stereo-seq | FFPE compatibility, sensitivity, analytical reproducibility, and adoption in scientific publications | Market acceptance in spatial omics |
| Consumables business | Reagent revenue, instrument utilization, and sustained improvements in gross margin | Sustainability of the business model |
| International expansion | Regulatory developments, local manufacturing and support, and customer acquisition | Growth potential outside China |
9.1 Opportunities Created by Multi-Omics Integration
One of the most interesting consequences of bringing CycloneSEQ and Stereo-seq into the same corporate group is the possibility of developing experimental workflows that combine technologies previously purchased and operated separately.
For example, an integrated cancer research workflow might involve:
- DNBSEQ: Short-read whole-genome sequencing and RNA-seq
- CycloneSEQ: Structural variant analysis, haplotype phasing, and complex splice isoform characterization
- Stereo-seq: Spatial gene expression analysis of the tumor microenvironment
- GLI: Automation of sample preparation, quality control, and data integration
If these capabilities are successfully integrated, MGI could provide a research platform that enables the combined interpretation of genomic variation, transcriptional regulation, cell-cell interactions, and tissue architecture.
However, this is a technologically attractive vision rather than an already completed solution.
Challenges remain in batch effect correction, sample quality control, data integration algorithms, and cost-effectiveness.
10. Overall Assessment: Where Is MGI Heading?
MGI's current strengths and challenges can be summarized as follows.
| Evaluation Area | Current Assessment |
|---|---|
| Short-read sequencing | Established and highly competitive technology; a credible option for numerous research applications |
| Long-read sequencing | Strategically valuable, but independent performance validation and market adoption remain critical |
| Spatial omics | Promising field built on MGI's distinctive high-density DNB technology |
| Financial performance and business model | Showing signs of recovery, but sustainable profitability has not yet been achieved |
| International competitiveness | Opportunities based on technology and pricing, balanced against regulatory and ecosystem challenges |
By 2026, describing MGI merely as a Chinese manufacturer offering a lower-cost replacement for Illumina is no longer adequate.
MGI is pursuing an ambitious strategy to integrate long-read sequencing, spatial omics, and laboratory AI, while continuing to rely on short-read sequencing as its primary revenue foundation.
However, future success will depend less on how many different technologies the company owns and more on whether it can establish an ecosystem that researchers and clinical laboratories find reliable, practical, well-supported, and economically sustainable.
Considering technological maturity, global competition, and geopolitical constraints, the next three to five years could be decisive in determining whether MGI remains primarily a major China-centered genomics instrument manufacturer or develops into a global multi-omics platform company.
10.1 Implications for the Future of Genomic Science
From the perspective of genomic science, the most interesting question may not be how much market share MGI can take from Illumina.
Rather, it is how significantly MGI can reshape the technological and economic boundaries between sequencing, spatial analysis, and cellular analysis.
Viewed from this perspective, MGI's future development could influence not only competition in the NGS instrument market but also the ways genomic research itself is conducted.
References
The following sources were used for this analysis as of November 1, 2026. Technical performance claims and strategic projections originating from corporate announcements or financial reports should be distinguished from independently validated findings.
[1] MGI Tech, “MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read, and Spatial Omics Solutions,” 2026. https://global-mgitech.com/mgi-tech-announces-acquisition-of-stomics-and-cycloneseq-to-deliver-integrated-long-read-short-read-and-spatial-omics-solutions/
[2] MGI Tech (华大智造), “2026 Third Quarter Report,” October 24, 2026. https://paper.cnstock.com/html/2026-10/24/content_2280694.htm
[3] MGI Tech, “2025 Annual Report,” 2026. https://financialfilings.com/filings/mgi-tech-co-ltd/annual-report/2026/66755377/
[4] FEBS Letters, “Comparison of Illumina and MGI single-cell RNA sequencing platforms,” 2025. https://doi.org/10.1002/1873-3468.70087
[5] MGI Tech, “HG002/NA24385 Whole-Genome Sequencing Benchmark Comparing DNBSEQ and Other Sequencing Platforms,” 2026. MGI-published comparative technical materials.
[6] MGI Tech, “DNBSEQ Product Portfolio and Technical Specifications,” December 2025. MGI official product documentation.
[7] MGI Tech, “CycloneSEQ Nanopore Sequencing Technology,” 2026. MGI official technical documentation.
[8] STOmics, “Stereo-seq Spatial Transcriptomics Technology and Specifications,” STOmics technical documentation.
[9] MGI Tech, “2025 Annual Report: Segment Revenue and Geographical Revenue,” 2026. https://financialfilings.com/filings/mgi-tech-co-ltd/annual-report/2026/66755377/
[10] MGI Tech, “2026 Interim Results: Sequencing Consumables and Instrument Revenue,” 2026. MGI interim financial reporting materials.
[11] Illumina / MGI, “Patent Litigation Settlement Agreement,” 2022. Publicly disclosed information regarding the U.S. patent litigation settlement between Illumina and MGI.
[12] Ropes & Gray, “BIOSECURE Act Enacted,” January 2026. https://www.ropesgray.com/en/insights/alerts/2026/01/biosecure-act-enacted